About M Dialysis
|
Microdialysis monitoring for improved health care!
M Dialysis AB develops and markets industry leading clinical microdialysis solutions for advanced clinical research and general intensive care usage. Our clinical microdialysis solutions are used across the globe by caregivers and researchers for improved health care.
Company Overview M Dialysis AB is a Swedish medical device and research company that is an offshoot from CMA Microdialysis AB that was founded in 1984.
M Dialysis's unique and market leading solutions are developed, produced and sold to clinicians and researchers to enable optimized patient care and accelerated drug development. The complete line of microdialysis instruments, consumables and computer software are used globally by universities, hospitals and pharmaceutical companies as unique tools for in vivo sampling and monitoring of organs and tissues. M Dialysis has distributors across the globe, responsible for local sales, service and support.
M Dialysis develops, produces and markets tissue monitoring solutions for neuro and reconstructive surgery. The company also offers clinical research solutions for many other applications such as Gastrointestinal, Hepatic, Muscle and Skin. Product portfolio is mainly based on the ISCUS platform and a broad range of tissue catheters. Ownership and Governance M Dialysis AB is a Swedish limited company and is represented in the USA through the subsidiary M Dialysis Inc. The CEO is Olof Nord, the former CEO of Dipylon Medical AB
History The concept of Microdialysis was born in the early 1970's. While examining the cross-section of a blood vessel among fluorescent nerve endings, Professor Urban Ungerstedt of the Karolinska Institute in Stockholm had the idea of using a dialysis tube as "an artificial blood capillary", in order to monitor chemical events in the tissue, see Microdialysis technique. The first paper on Microdialysis was published in 1974. Since then, more than 13.000 scientific papers have been published on the technique - among them some 2.000 clinical investigations. |
